Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment
Biotechnology firm Humacyte’s (HUMA) shares have declined since the company presented its fourth-quarter and full-year 2024 results. The ...
Nasdaq8h
Stock Splits
Discover which stocks are splitting, the ratio, and split ex-date with the latest information from EDGAR® Online LLC. Data provided by and © 2024 EDGAR® Online LLC ...
Zacks Investment Research on MSN18h
Humana Gains on Strong Membership Base and Sound Cash Reserves
Humana Inc. HUM remains well-poised for growth on the back of improved premium revenues, an aging U.S. population, acquisitions and adequate cash generation abilities. A strong 2025 outlook reinforces ...